周三，部分生物制药公司股价飙升，截至发稿，Replimune(REPL.US)飙升逾85%， Sarepta Therapeutics (SRPT.US)上涨超16%， Capricor Therapeutics(CAPR.US)大涨超18%。消息面上，美国FDA生物制品评 估与研究中心主任普拉萨德在上任不到三个月后离职，正值FDA对多款基因疗法和疫苗采取严格监管措 施，引发市场关注。分析人士指出，他的离任可能有助于缓解监管压力，被视为基因疗法和疫苗企业的 利好消息。 ...

智通财经APP获悉，周三，部分生物制药公司股价飙升，截至发稿，Replimune(REPL.US)飙升逾85%， Sarepta Therapeutics (SRPT.US)上涨超16%，Capricor Therapeutics(CAPR.US)大涨超18%。消息面上，美 国FDA生物制品评估与研究中心主任普拉萨德在上任不到三个月后离职，正值FDA对多款基因疗法和疫 苗采取严格监管措施，引发市场关注。分析人士指出，他的离任可能有助于缓解监管压力，被视为基因 疗法和疫苗企业的利好消息。 ...

NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Sarepta Therapeutics, Inc. (NASDAQ: SRPT) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Sarepta, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/sarepta-therapeutics-inc-class-action. Investors have until August 25, 2025, to as ...

Last week, Sarepta voluntarily and temporarily paused all U.S. shipments of Elevidys. Elevidys had received traditional approval in June 2024 for ambulatory Duchenne muscular dystrophy (DMD) patients aged four years and older with a confirmed DMD gene mutation. Previously, in June 2023, it secured accelerated, conditional approval for non-ambulatory DMD patients. As gene therapies continue to evolve as a promising frontier in medical treatment, regulatory scrutiny intensifies following safety concerns. Rece ...

Sarepta Soars After FDA Says Some Patients Can Get Elevidys. Hear about the winners and losers on Wall Street with the Bloomberg Stock Movers report. https://t.co/CnwR9un0jS ...

近日，美国食品药品管理局（FDA）调查结果显示，一名八岁男童的死亡事故与Sarepta的基因疗法"无 关"。 （文章来源：华尔街见闻） 罗氏制药将恢复在美国市场之外的基因疗法Elevidys发货工作。 ...

POLAND - 2025/01/25: In this photo illustration, the Sarepta Therapeutics company logo is seen ... More displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images) Sarepta's current distressed valuation makes it an attractive acquisition candidate for larger pharmaceutical companies seeking gene therapy capabilities. The company's expertise, intellectual property, and market-leading position in Duchenne treatments could command significant premiums in a take ...

NEW YORK, July 29, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sarepta investors who were adversely affected by alleged securities fraud between June 22, 2023 and June 24, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/sarepta-lawsuit-submissio ...

Shares of Sera Therapeutics up by about 36% in the pre-market. The company says that it will resume shipping Alvdus, that's a muscular disorder gene therapy to patients who can walk. Last week, the FDA recommended a pause in shipments because of serious safety concerns after three deaths of patients who were on this who were on serene therapies. This past weekend, there were reports of a death of another child on Avdus, but the death, the FDA now says, was unrelated to the gene therapy. In a statement, Surr ...

Group 1 - Major stock index futures are showing positive movement, with Dow futures up 0.16%, S&P 500 futures up 0.24%, and Nasdaq futures up 0.40% [1] - Technology stocks are mostly rising, with Nvidia up over 1.5% and AMD and Advanced Micro Devices up over 1% [2] - Some Chinese concept stocks are experiencing significant gains, with Li Auto up over 4%, Global Data up over 3%, and Miniso and NIO up over 1% [2] Group 2 - Nvidia reportedly placed an order for 300,000 H20 chips from TSMC, contributing to its pre-market rise of over 1.5% [4] - Sarepta Therapeutics saw a pre-market surge of over 40% after the FDA authorized the resumption of its gene therapy Elevidys for treating Duchenne muscular dystrophy [5] - Apple announced the closure of its first direct store in China, located in Dalian, due to the departure of several retailers from the shopping center, with the store set to close on August 9, 2025 [6] Group 3 - Ford has signed a new $3 billion term loan agreement, which will last until July 28, 2026, with drawn loans maturing on December 31, 2028 [8] - Stellantis reported a 13% year-over-year decline in net revenue for the first half of 2025, totaling €74.3 billion, primarily due to declines in North America and Europe, resulting in a net loss of €2.3 billion compared to a net profit of €5.6 billion in the same period last year [9]